Literature DB >> 25058813

Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema.

Jennifer K Sun1, Michael M Lin2, Jan Lammer3, Sonja Prager4, Rutuparna Sarangi5, Paolo S Silva1, Lloyd Paul Aiello1.   

Abstract

IMPORTANCE: Biomarkers that predict future visual acuity (VA) in eyes with baseline diabetic macular edema (DME) would substantively improve risk assessment, management decisions, and selection of eyes for clinical studies targeting DME.
OBJECTIVE: To determine whether baseline or early change in the novel spectral domain-optical coherence tomography (SD-OCT) parameter disorganization of the retinal inner layers (DRIL) is predictive of VA in eyes with center-involved DME. DESIGN, SETTING, AND PARTICIPANTS: At a tertiary care referral center for diabetic eye disease, a retrospective, longitudinal cohort study obtained demographics, VA, and SD-OCT images from baseline, 4-month, and 8-month visits in 96 participants (120 eyes) with diabetes mellitus and baseline center-involved DME (SD-OCT central subfield thickness, ≥ 320 µm for men and ≥ 305 µm for women). Exclusion criteria included substantial media opacity, cataract surgery within 6 months, and nondiabetic retinal pathology affecting VA. On SD-OCT, the 1-mm-wide retinal area centered on the fovea was evaluated by masked graders for DRIL extent, cysts, hyperreflective foci, microaneurysms, cone outer segment tip visibility, and external limiting membrane or photoreceptor disruption and reflectivity. MAIN OUTCOMES AND MEASURES: Visual acuity and SD-OCT-derived retinal morphology.
RESULTS: Greater DRIL extent at baseline correlated with worse baseline VA (point estimate, 0.04; 95% CI, 0.02-0.05 per 100 µm; P < .001). An increase in DRIL during 4 months was associated with VA worsening at 8 months (point estimate, 0.03; 95% CI, 0.02-0.05 per 100 µm; P < .001). A multivariate model that included a 4-month change in VA, DRIL, and external limiting membrane disruption was predictive of an 8-month VA change (r = 0.80). Each approximately 300-µm DRIL increase during 4 months predicted a 1-line, 8-month VA decline. When DRIL increased at least 250 µm at 4 months, no eyes had VA improvement of at least 1 line at 8 months. When DRIL decreased at least 250 µm at 4 months, no eyes had VA decline of at least 1 line at 8 months, and 77.7% had VA improvement of at least 1 line. CONCLUSIONS AND RELEVANCE: Disorganization of the retinal inner layers in the 1-mm foveal area is associated with VA, and change in DRIL predicts future change in VA. Early change in DRIL prospectively identifies eyes with a high likelihood of subsequent VA improvement or decline. Therefore, DRIL warrants further study as a robust, readily obtained, and noninvasive biomarker of future VA response in eyes with DME.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25058813     DOI: 10.1001/jamaophthalmol.2014.2350

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  119 in total

1.  Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study.

Authors:  Berna Evranos Ogmen; Nagihan Ugurlu; Sevgül Faki; Sefika Burcak Polat; Reyhan Ersoy; Bekir Cakir
Journal:  Int Ophthalmol       Date:  2021-01-22       Impact factor: 2.031

Review 2.  Therapeutic Options in Refractory Diabetic Macular Oedema.

Authors:  Sanket U Shah; Raj K Maturi
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

3.  Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.

Authors:  Katja Hatz; Andreas Ebneter; Cengiz Tuerksever; Christian Pruente; Martin Zinkernagel
Journal:  Ophthalmologica       Date:  2018-02-02       Impact factor: 3.250

4.  Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration.

Authors:  Stephanie K Lynch; Kyungmoo Lee; Zhi Chen; James C Folk; Ursula Schmidt-Erfurth; Bianca S Gerendas; Andreas Wahle; Charles C Wykoff; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

Review 5.  Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.

Authors:  Elia J Duh; Jennifer K Sun; Alan W Stitt
Journal:  JCI Insight       Date:  2017-07-20

Review 6.  A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping.

Authors:  Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Vision Res       Date:  2017-08-02       Impact factor: 1.886

7.  Visualizing Structure and Vascular Interactions: Macular Nonperfusion in Three Capillary Plexuses.

Authors:  Justin J Park; Christopher S Chung; Amani A Fawzi
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2018-11-01       Impact factor: 1.300

8.  Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.

Authors:  Amy S Babiuch; Michael Han; Felipe F Conti; Karen Wai; Fabiana Q Silva; Rishi P Singh
Journal:  JAMA Ophthalmol       Date:  2019-01-01       Impact factor: 7.389

9.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

10.  Association of Diabetic Macular Nonperfusion With Outer Retinal Disruption on Optical Coherence Tomography.

Authors:  Fabio Scarinci; Lee M Jampol; Robert A Linsenmeier; Amani A Fawzi
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.